Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant meningococcal group b vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant meningococcal group B vaccine is an investigational prophylactic vaccine candidate developed by Beijing Zhifei Lvzhu Biopharmaceutical for prevention of disease caused by *Neisseria meningitidis* serogroup B. The candidate is produced using an *Escherichia coli* expression system and has been evaluated in a randomized, double-blind, placebo-controlled Phase 1 study in participants aged 3 months to 50 years to assess safety, tolerability, and preliminary immunogenicity. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/ce426554000842929d87091b39739a1e))
- Other names
- recombinant meningococcal group b vaccine e. colirecombinant group b meningococcal vaccine e. coli
02
Targets
NadA (Neisserial adhesin A)NHBA (Neisserial heparin-binding antigen)PorA (Major outer membrane protein PorA)fHbp (Factor H-binding protein)CFH (Complement factor H)
Beyond the preview
Go deeper on recombinant meningococcal group b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant meningococcal group b vaccine.